Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Thrice-Weekly Hemodialysis Clear all
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

NCT04410198
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease (ESRD)
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Englewood, Colorado • Caldwell, Idaho • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 27, 2026, 4:36 PM EDT
Completed No phase listed Observational

Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment

NCT01092455
View directory record Official record
Conditions
Renal Dialysis
Interventions
Heparin N reduction
Drug
Lead sponsor
Randolph Quinn
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 27, 2026, 4:36 PM EDT
Completed No phase listed Observational

Blood Volume Analysis and Related Outcomes in Hemodialysis

NCT01679249
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Not listed
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 27, 2026, 4:36 PM EDT
Not yet recruiting Not applicable Interventional

Dry Weight Reduction Intervention Via Extra Ultrafiltration

NCT07637110
View directory record Official record
Conditions
Fluid Accumulation, Blood Pressure Management, End Stage Renal Disease (ESRD)
Interventions
Ultrafiltration
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 27, 2026, 4:36 PM EDT
Recruiting Not applicable Interventional

Incremental Hemodialysis: The TwoPlus Trial

NCT05828823
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Hemodialysis twice weekly, Hemodialysis thrice weekly
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Jacksonville, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

NCT04484857
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 27, 2026, 4:36 PM EDT
Active, not recruiting Not applicable Interventional

Virtual Reality in Hemodialysis to Improve Psychological Well-being

NCT05642364
View directory record Official record
Conditions
End Stage Kidney Disease, Depressive Symptoms
Interventions
Joviality(TM), Inert Virtual Reality
Behavioral · Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Not applicable Interventional Results available

Premarket Clinical Safety Assessment of the ELISIO™-HX

NCT07058909
View directory record Official record
Conditions
Renal Failure, Acute Renal Failure, Chronic Renal Failure, Chronic Kidney Diseases, End Stage Renal Disease
Interventions
ELISIO™-HX Dialyzer
Device
Lead sponsor
Nipro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01628107
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
108
States / cities
Azusa, California • Bellflower, California • Commerce, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 27, 2026, 4:36 PM EDT
Terminated Not applicable Interventional

Recovery After Dialysis-Requiring Acute Kidney Injury

NCT03305549
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Conservative dialysis strategy, TIW dialysis strategy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 27, 2026, 4:36 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

NCT06609343
View directory record Official record
Conditions
End Stage Renal Disease, Fatigue
Interventions
Bupropion Hydrochloride 150 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
25 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

NCT01922843
View directory record Official record
Conditions
Hyperparathyroidism, Secondary, Kidney Failure, Chronic
Interventions
DP001 softgel capsules, Placebo
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

NCT01785875
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

NCT01785849
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function

NCT03546205
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
JNJ-64565111
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Not applicable Interventional

Pomegranate and Hemodialysis Pilot Trial

NCT01562340
View directory record Official record
Conditions
End Stage Renal Disease, Cardiovascular Disease, Inflammation
Interventions
Pomegranate juice, Pomegranate fruit extract
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

NCT01628120
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
115
States / cities
Azusa, California • Bakersfield, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease

NCT03740048
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Hemodialysis, Patiromer Oral Product
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

NCT02689206
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, GSK1278863 matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Northridge, California • San Dimas, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Not applicable Interventional

Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin

NCT00597025
View directory record Official record
Conditions
End Stage Renal Disease, Hypoalbuminemia, Malnutrition
Interventions
Protein Food Bar Intelligent Indulgence
Dietary Supplement
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 27, 2026, 4:36 PM EDT
Completed No phase listed Observational

T-Wave Alternans in Dialysis Patients

NCT00621426
View directory record Official record
Conditions
Sudden Cardiac Death, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153
View directory record Official record
Conditions
Anemia
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 27, 2026, 4:36 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease (CKD)
Interventions
Vadadustat, Mircera®
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
58
States / cities
Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 27, 2026, 4:36 PM EDT